3B Blackbio DX Q3 FY24 earnings call: Revenue & Margins
Q3 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹18Cr
- +20% YoY
- −5.3% QoQ
- Net profit
- ₹9Cr
- +12.5% YoY
- +12.5% QoQ
- Margin
- 50%
- 0 pp YoY
- +9 pp QoQ
Guidance rank: #34 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
Based on 3B Blackbio DX Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3 FY 2023-24 Diagnostics Business Revenue: ₹1,531.37 lakh (including ₹11.63 lakh COVID sales) vs ₹1,043.99 lakh in Q3 FY 2022-23; over 30% effective growth YoY (Page 15). Q3 FY 2023-24 EBITDA: ₹1,004.31 lakh vs ₹1,170.47 lakh in Q3 FY 2022-23 (YoY decrease) - Q3 FY 2023-24 Profit After Tax (PAT): ₹769.37 lakh vs ₹873.96 lakh in Q3 FY 2022-23 (YoY decrease) - Revenue fr
From 3B Blackbio DX Ltd's Q3 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY 2023-24 Diagnostics Business Revenue: ₹1,531.37 lakh (including ₹11.63 lakh COVID sales) vs ₹1,043.99 lakh in Q3 FY 2022-23; over 30% effective growth YoY (Page 15).
- Export sales for molecular diagnostic kits in Q3 FY 2023-24: ₹267.20 lakh vs ₹219.89 lakh in Q3 FY 2022-23 (Page 15).
- Consolidated Q3 FY 2023-24 Total Revenue: ₹2,029.65 lakh vs ₹1,760.85 lakh in Q3 FY 2022-23 (Page 5).
- Consolidated Q3 FY 2023-24 Profit Before Tax: ₹1,115.20 lakh vs ₹989.68 lakh in Q3 FY 2022-23 (Page 5).
- Consolidated Q3 FY 2023-24 Profit After Tax: ₹851.69 lakh vs ₹771.40 lakh in Q3 FY 2022-23 (Page 5).
2 more points from 3B Blackbio DX Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 25).
- The amalgamation scheme with 3B BlackBio Biotech India Ltd is completed, creating a merged entity 3B BlackBio Dx Ltd, which is fully functional (Page 25).
- The UK subsidiary, TRUPCR® Europe Limited in Manchester, has moved to a larger, state-of-the-art facility with dedicated labs for Production, QC, R&D, and storage/dispatch (Page 20).
2 more points from 3B Blackbio DX Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what 3B Blackbio DX Ltd said on order book & pipeline — free account, 30 seconds.
3B Blackbio DX Ltd — Quarterly revenue & net profit
3B Blackbio DX Ltd Q3 FY24 results — key figures
| ₹ Cr | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue | 18 | 15 | +20% | 19 | -5.3% |
| Operating profit (EBITDA) | 9 | 7 | +28.6% | 8 | +12.5% |
| Operating margin | 50% | 50% | 0 pp | 41% | +9 pp |
| Profit before tax | 11 | 10 | +10% | 10 | +10% |
| Net profit (PAT) | 9 | 8 | +12.5% | 8 | +12.5% |
| EPS (₹) | 10.16 | 8.96 | +13.4% | 10.46 | -2.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio's management said in earlier quarters
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q3 FY24 results?
Q3 FY 2023-24 Diagnostics Business Revenue: ₹1,531.37 lakh (including ₹11.63 lakh COVID sales) vs ₹1,043.99 lakh in Q3 FY 2022-23; over 30% effective growth YoY (Page 15). Q3 FY 2023-24 EBITDA: ₹1,004.31 lakh vs ₹1,170.47 lakh in Q3 FY 2022-23 (YoY decrease) - Q3 FY 2023-24 Profit After Tax (PAT): ₹769.37 lakh vs ₹873.96 lakh in Q3 FY 2022-23 (YoY decrease) - Revenue fr
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 25).
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
